(Q38021821)

English

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation

scientific article published on September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1 reference

based on heuristic

inferred from title

atrial fibrillation

1 reference

based on heuristic

inferred from title

1

object named as

Kate McKeage

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

publication date

1 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

841-855

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

https://scigraph.springernature.com/pub.10.2165/11209130-000000000-00000

0 references

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Update on atrial fibrillation: part I.

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Stroke severity in atrial fibrillation. The Framingham Study

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

The cost of illness of atrial fibrillation: a systematic review of the recent literature

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

A review of the cost of atrial fibrillation

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Epidemiology and outcomes in patients with atrial fibrillation in the United States

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Dabigatran: a review of clinical and pharmacoeconomic evidence.

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds

1 reference

https://api.crossref.org/works/10.2165%2F11209130-000000000-00000

21 January 2018

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Newly identified events in the RE-LY trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dabigatran compared with warfarin for stroke prevention in atrial fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22734683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11209130-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38021821&oldid=2174225866"